At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PTPI Petros Pharmaceuticals, Inc.
Trading 10-01 12:21:11 EDT Delay
Petros Pharmaceuticals Initiates Liquidation and Leadership Changes
TIPRANKS  ·  10-01 05:29
Petros Pharmaceuticals Initiates Liquidation and Leadership Changes
Petros Pharmaceuticals - Ceases Substantially All Business Operations - SEC Filing
THOMSON REUTERS  ·  10-01 05:11
Petros Pharmaceuticals - Ceases Substantially All Business Operations - SEC Filing
Petros Pharmaceuticals - All Outstanding Obligations May be Immediately Due; Series a Convertible Preferred Stock to be Redeemed - SEC Filing
THOMSON REUTERS  ·  10-01 05:11
Petros Pharmaceuticals - All Outstanding Obligations May be Immediately Due; Series a Convertible Preferred Stock to be Redeemed - SEC Filing
Petros Pharmaceuticals - Assigns All Assets to PT Liquidation, for Benefit of Creditors - SEC Filing
THOMSON REUTERS  ·  10-01 05:11
Petros Pharmaceuticals - Assigns All Assets to PT Liquidation, for Benefit of Creditors - SEC Filing
Petros Net Loss Narrows 40.06% to $1.94 Million in 1H FY26; SG&A Drops 38.2% to $2.02 Million
Reuters  ·  08-14
Petros Net Loss Narrows 40.06% to $1.94 Million in 1H FY26; SG&A Drops 38.2% to $2.02 Million
Petros Pharmaceuticals Chief Accounting Officer Robert Weinstein Files Initial Beneficial Ownership Statement
Reuters  ·  06-26
Petros Pharmaceuticals Chief Accounting Officer Robert Weinstein Files Initial Beneficial Ownership Statement
Petros Pharmaceuticals Appoints New Chief Accounting Officer
TIPRANKS  ·  06-19
Petros Pharmaceuticals Appoints New Chief Accounting Officer
Petros Pharmaceuticals appoints Robert Weinstein chief accounting officer, principal financial officer
Reuters  ·  06-19
Petros Pharmaceuticals appoints Robert Weinstein chief accounting officer, principal financial officer
Petros Pharmaceuticals Grants Targeted Equity Awards to Leadership
TIPRANKS  ·  06-06
Petros Pharmaceuticals Grants Targeted Equity Awards to Leadership
Petros net loss narrows to $987,036 in Q1 FY26
Reuters  ·  05-14
Petros net loss narrows to $987,036 in Q1 FY26
Toro Corp. CEO Makes Bold Multi-Million Dollar Bet on His Own Company
TIPRANKS  ·  04-25
Toro Corp. CEO Makes Bold Multi-Million Dollar Bet on His Own Company
Petros swings to FY25 net income of 1.9 million; operating loss edges up 0.3% to 4.6 million
Reuters  ·  04-16
Petros swings to FY25 net income of 1.9 million; operating loss edges up 0.3% to 4.6 million

Introduction

Company Name.
Petros Pharmaceuticals, Inc.
Affiliated Markets:
PINK LIMITED
Listing Date:
--
Main Business:
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
Issue price:
--